title: The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis.
abstract: Increased patient longevity and aggressive antibiotic treatment are thought to impact on the microbial composition of the airways of adults with cystic fibrosis (CF). In this study, we sought to determine if a temporal change in the airway microbiology of adults with CF has occurred over time.
  
  
  
  Longitudinal analysis of sputum microbiology results was undertaken on patients attending a large adult CF centre. Clinical status and health outcomes of transitioning patients were also assessed.
  
  
  
  A decrease in the prevalence of Pseudomonas aeruginosa, Staphylococcus aureus, Burkholderia cepacia complex and Aspergillus spp. (p=0.001, p<0.001, p=0.002 and p<0.001, respectively) occurred. Improvements in lung function among transitioning patients infected with P. aeruginosa were observed.
  
  
  
  Overtime, a decline in the prevalence of many CF airway pathogens has occurred. Significantly, an incremental improvement in lung function was reported for transitioning patients with current P. aeruginosa infections.
authors: Lung Bacteria Group, QIMR Berghofer Medical Research Institute, Herston Rd, Herston, Brisbane, Australia; School of Medicine, The University of Queensland, Herston Rd, Herston, Brisbane, Australia. Electronic address: kay.ramsay@qimrberghofer.edu.au.
authors: Kay A
authors: KA
authors: Ramsay
authors: Severn Postgraduate Medical Education (PGME) School of Primary Care, Office of General Practice, The Academy, Great Western Hospital, Marlborough Road, Swindon, United Kingdom. Electronic address: harps.k.sandhu@gmail.com.
authors: Harpreet
authors: H
authors: Sandhu
authors: Department of Thoracic Medicine, Royal Adelaide Hospital, North Tce, Adelaide, Australia; Respiratory Medicine, Lyell McEwin Hospital, Haydown Rd, Elizabeth Vale, Adelaide, Australia. Electronic address: James.Geake@sa.gov.au.
authors: James B
authors: JB
authors: Geake
authors: Statistics Unit, QIMR Berghofer Medical Research Institute, Herston Rd, Herston, Brisbane, Australia. Electronic address: Emma.Ballard@qimrberghofer.edu.au.
authors: Emma
authors: E
authors: Ballard
authors: Statistics Unit, QIMR Berghofer Medical Research Institute, Herston Rd, Herston, Brisbane, Australia. Electronic address: Peter.O'Rourke@qimrberghofer.edu.au.
authors: Peter
authors: P
authors: O'Rourke
authors: School of Medicine, The University of Queensland, Herston Rd, Herston, Brisbane, Australia; Lady Cilento Children's Hospital, Stanley St, South Brisbane, Australia. Electronic address: Claire.Wainwright@health.qld.gov.au.
authors: Claire E
authors: CE
authors: Wainwright
authors: Lung Inflammation and Infection Group, QIMR Berghofer Medical Research Institute, Herston Rd, Herston, Brisbane, Australia; Department of Thoracic Medicine, The Prince Charles Hospital, Rode Rd, Chermside, Brisbane, Australia. Electronic address: David.Reid@qimrberghofer.edu.au.
authors: David W
authors: DW
authors: Reid
authors: School of Chemistry and Molecular Biosciences, The University of Queensland, Cooper Rd, Brisbane, Australia; Centre for Experimental Medicine, Queen's University Belfast, University Rd, Belfast, United Kingdom; Child Health Research Centre, The University of Queensland, Graham St, South Brisbane, Australia. Electronic address: t.m.kidd@uq.edu.au.
authors: Timothy J
authors: TJ
authors: Kidd
authors: Lung Bacteria Group, QIMR Berghofer Medical Research Institute, Herston Rd, Herston, Brisbane, Australia; School of Medicine, The University of Queensland, Herston Rd, Herston, Brisbane, Australia; Department of Thoracic Medicine, The Prince Charles Hospital, Rode Rd, Chermside, Brisbane, Australia. Electronic address: Scott.Bell@qimrbeghofer.edu.au.
authors: Scott C
authors: SC
authors: Bell
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001315:Australia / Q000453:epidemiology; D019121:Burkholderia Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D042602:Burkholderia cepacia complex / Q000302:isolation & purification*; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D015995:Prevalence; D011552:Pseudomonas Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification*; D012129:Respiratory Function Tests / Q000379:methods; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D013183:Sputum / Q000382:microbiology; D013203:Staphylococcal Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D013211:Staphylococcus aureus / Q000302:isolation & purification*; D060305:Transition to Adult Care / Q000706:statistics & numerical data
chemical_list: D000900:Anti-Bacterial Agents
keywords: Lung function; Paediatric; Prevalence; Pseudomonas aeruginosa; Transition